The FDA has approved Seattle Genetics' breast cancer drug Tukysa (tucatinib) four months early, including in certain patients whose disease has spread to the brain.
The FDA has approved a combination of Pfizer’s Braftovi and Merck KGaA’s Erbitux for a form of untreated metastatic colorectal cancer, the first targeted drug regimen for this form of the d
